In order to tailor the site to your needs, please click the button that relates best to you.
So long as you have cookies enabled you will only need to do this once. However, you can change your selection at any time using the dropdown navigation option above the CESPHN logo, top left.
There are now cases of COVID-19 linked to the Bondi cluster. Click here for all the latest information relating to the NSW outbreak including case locations and alerts. There are many venues listed across the region with concentrations in Bondi Junction, Vaucluse, Sydney city and Drummoyne.
See here or check our website for information on the latest testing locations within the region. Numerous new pop-up clinics have been established and anyone with symptoms or who has been to identified case locations should get tested.
PPE guidelines were amended on 10 June and can be found here. To order masks for your practice click here. We are also doubling mask orders to ensure general practice and other primary care providers have adequate masks for their practice.
We would also like to remind all general practices of the importance of encouraging those aged 60 and over to receive the Astra Zeneca vaccine and for those who have had their first dose with no serious adverse events to come back for their second dose to ensure greater protection from COVID-19.
CESPHN webinar: 30 June
Join us for a one-hour webinar next Wednesday 30 June at 7.00 pm on the COVID-19 outbreak and key challenges. Speakers will include Dr Vicky Sheppeard, Acting Director South Eastern Sydney Public Health Unit, providing the latest information on the current outbreak, and Dr Brendan Goodger from CESPHN providing an update on the vaccine rollout in this region.
On 17 June, the Australian Technical Advisory Group on Immunisation announced new recommendations relating to the administration of the AstraZeneca vaccine. Pfizer is now the preferred vaccine for those aged 16 to under 60 years (previously 50 years). The recommendation has been revised due to the higher risk and observed severity of thrombosis and thrombocytopenia syndrome (TTS) related to the use of AstraZeneca in Australia in the 50-59 age group.
People aged 50-59 who are booked for their first dose of COVID-19 vaccine should be offered the Pfizer vaccine instead of AstraZeneca. All people who are offered AstraZeneca should be advised of the risk of TTS, the symptoms to watch out for in the 4-30 days post-vaccine and when to seek medical advice.
Symptoms of TTS include new onset of:
Persistent headaches with or without changes in vision, other focal neurology or seizure-like activity
Persistent abdominal pain
Leg swelling or pain with or without associated colour change
Chest pain and/or shortness of breath (without a clear alternative cause)
Following the recent Expression of Interest, 80 general practices will begin administering the Pfizer vaccine in the region over the next month. We expect additional practices to commence administering the vaccine in the coming months as vaccine supply increases.
New MBS patient assessment items
From 18 June 2021, the Australian Government introduced two new MBS (10660 and 10661) to support General Practitioners and Other Medical Practitioners to provide in-depth clinical assessments of patients aged 50 years and over regarding patients’ individual health risks and benefits associated with receiving a COVID-19 vaccine.
MBS items 10660 and 10661 may only be claimed where a GP or OMP attends to a patient in person for more than 10 minutes.
The item must be billed in association with a relevant MBS COVID-19 vaccine suitability assessment item.
Consistent with the other MBS vaccine suitability assessment items, items 10660 and 10661 must be bulk-billed
Further information on the In-depth Patient Assessment items is provided in theItem descriptors and Fact Sheet.
Addressing vaccine hesitancy
The Conversation published an article last week with some helpful statistics and graphics that may be useful in discussions with patients around vaccine hesitancy.
“Two people in Australia have died from TTS after 3.8 million doses of the AstraZeneca vaccine delivered. This makes the likelihood of dying from this syndrome about 0.5 in a million, or if you prefer whole numbers, about 1 in 2 million.”
The below graph shows the risk of dying from a TTS blood clot after a dose of AstraZeneca, compared to the risk of death from activities such as a car accident or lighting strike.
Welcome to our new website! As you may have noticed, our website looks different. Central and Eastern Sydney PHN have moved to a new site and although much has remained the same, we have introduced some new functions. These include: Updated navigation When you land on our new website, you…
COVID-19 weekly update – 02 JANUARY 2023 COVID-19 cases in the region Please note: From next week the latest COVID-19 information will be included in the Sydney Health Weekly newsletter, rather than separated at the top. We will still provide COVID-19 related information as well as the dedicated COVID-19 latest…
FIVE QUESTIONS is where we ask members of the community to talk about how they stay HEALTHY. Randwick scientist and grandmother Hilda Stender shared this: What exercise did you do yesterday? I’ve had two knee replacements – one four years ago and the other six months ago. As a result,…
Immunisation weekly update – 1 February 2023 Childhood immunisation overdue reports CESPHN is inviting general practices to sign up to receive a regular report extracted on your behalf from the Australian Immunisation Register (AIR) which is specific to your practice. This report contains all children aged 0-5 living in the CESPHN region…
Australian Digital Health Agency (ADHA) digital health webinars Implementing MyHealth Record Policies in your organisation Thu 9 Feb 23, 12.30-1.00 pm – learn how to implement and maintain a My Health Record Security and Access policy in your organisation. Understand the importance of the Responsible Officer (RO) and Organisational Maintenance…
UNSW research – Palliative care and intellectual disability A research team led by Professor Julian Trollor at the Department of Developmental Disability Neuropsychiatry, UNSW Sydney, aims to design, implement, and evaluate a new palliative care service for people with intellectual disability. This is important because people with intellectual disability often…
GP support needed: Shared e-Care plan study for follow-up of colorectal and breast cancers This research evaluates shared care using a new interactive e-care plan being implemented through cancer services in Prince of Wales and St George public and private hospitals. Through the e-care plan GPs, cancer specialists and patients…